68Ga-PSMA-R2 in Patients With Biochemical Relapse (BR) and Metastatic Prostate Cancer (mPCa)

NCT ID: NCT03490032

Last Updated: 2020-11-17

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 30 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-05-23
• Study Completion Date: 2019-09-13

Brief Summary

This was an open-label, multicenter, single dose, Phase I/II study to evaluate the safety and tolerability of a single administration of 3 mega Becquerel (MBq)/kg, but not less than 150 MBq and not more than 250 MBq, of 68^Ga-PSMA-R2 in adult male patients with biochemical relapse (BR) and metastatic prostate cancer (mPCa).

Detailed Description

This study consisted of 2 parts.

• During the first part (Phase I) of the study, 6 subjects with biochemically recurrent prostate cancer (PCa) received the investigational product (IP) and remained at the site for approximately 6 hours post-administration in order to assess the PK, biodistribution versus time, and dosimetry for critical organs. Subjects received a single dose of 3 MBq/kg, (>=150 and =<250 MBq), of 68^Ga-PSMA-R2 intravenously. Serial blood and urine samples were collected for PK characterization and dosimetry and whole-body PET/CT were acquired at selected time points (0 to 4 hours) to determine organ and tumor absorbed doses. Safety assessments were conducted after IP administration on Day 1, and during follow-up on Days 7 and 28.
• In the second part of the study (Phase II), 2 groups of 12 subjects were enrolled (subjects with PCa in biochemical recurrence [PCa-BR], and subjects with prostate cancer in the metastatic stage [mPCa]). Based on the preliminary data analysis from the Phase I part of the study provided sufficient dosimetry data, all subjects underwent the whole body PET/CT imaging optimized for time (up to 2 time points) according to the data analysis from the Phase I part of the study.

This study was comprised of 4 clinical visits and conducted in 3 study periods: screening, administration/imaging, and safety follow-up period.

Conditions

Prostate Cancer Metastatic

Keywords

Prostatic Neoplasms; Cancer of Prostate; Cancer of the Prostate; Neoplasms, Prostate; Prostate Cancer; Prostatic Cancer; Genital Neoplasms, Male; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Genital Diseases, Male; Prostatic Diseases; PSMA; Prostate-specific membrane antigen; Gallium radioisotope 68; 68Ga-PSMA-R2; 68Ga-PSMA ligand

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: DIAGNOSTIC
• Blinding Strategy: NONE

Study Groups

Biochemically Recurrent Prostate Cancer (PCa-BR) (Phase I)

All eligible participants received recommended dose of \[68Ga\]-PSMA-R2 of 3 Mega Becquerel (MBq)/Kg (+/- 10%) \[but not more than 250 and not less than 150 MBq\].

Group Type: EXPERIMENTAL

[68Ga]-PSMA-R2

Intervention Type: DRUG

radio-labelled PSMA ligand

Biochemically Recurrent Prostate Cancer (PCa-BR) (Phase II)

All eligible participants received recommended dose of \[68Ga\]-PSMA-R2 of 3 Mega Becquerel (MBq)/Kg (+/- 10%) \[but not more than 250 and not less than 150 MBq\].

Group Type: EXPERIMENTAL

[68Ga]-PSMA-R2

Intervention Type: DRUG

radio-labelled PSMA ligand

Metastatic Prostate Cancer (mPCa) (Phase II)

All eligible participants received recommended dose of \[68Ga\]-PSMA-R2 of 3 Mega Becquerel (MBq)/Kg (+/- 10%) \[but not more than 250 and not less than 150 MBq\].

Group Type: EXPERIMENTAL

[68Ga]-PSMA-R2

Intervention Type: DRUG

radio-labelled PSMA ligand

Interventions

[68Ga]-PSMA-R2

radio-labelled PSMA ligand

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Males 18 years or older.

2. Signed and dated written informed consent by the subject prior to any study-specific procedures.

3. Histologically confirmed adenocarcinoma of the prostate, defined as follows:

1. Biochemical recurrence: defined as PSA is ≥0.2 ng/mL after radical prostatectomy or PSA nadir plus 2 ng/mL after radiation therapy with corresponding CT/MRI or bone scan revealing absence of local recurrence or metastatic lesions.

OR

2. Metastatic disease: defined as both, castration-sensitive or castration-resistant mPCa (presence of at least 1 metastatic lymph node, visceral metastasis and/or bone metastasis).

3. At least 2 weeks must have elapsed between last anticancer treatment administration and the administration of the imaging product, 68Ga-PSMA-R2.

4. Prior major surgery must be at least 12 weeks prior to study entry.

5. Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2, with a life expectancy ≥6 months.

6. Adequate bone marrow reserve and organ function as demonstrated by complete blood count, and biochemistry in blood and urine at Screening:

1. Hemoglobin (Hb): >8 g/dL

2. Platelet count of >50.000/mm3

7. Serum creatinine <1.5*upper limit normal (ULN) or estimated glomerular filtration rate (eGFR) >50 mL/min based upon The Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation.

8. For male subjects with partners of childbearing potential, agreement to use barrier contraceptive method (condom) and to continue its use for 28 days after IP administration.

Exclusion Criteria

1. Pathological finding consistent with small cell, neuroendocrine carcinoma of the prostate or any other histologies different than adenocarcinoma.

2. Administered a radioisotope =<10 physical half-lives prior to the day of PET/CT.

3. Current severe urinary incontinence, hydronephrosis, severe voiding dysfunction, or need of indwelling/condom catheters.

4. Uncontrolled pain or incompatibility that results in subject's lack of compliance with imaging procedures.

5. Other known coexisting malignancies except non-melanoma skin or low grade superficial bladder cancer unless definitively treated and proven no evidence of recurrence for 5 years.

6. Subject with known incompatibility to CT scans.

7. Any evidence of severe or uncontrolled systemic or psychiatric diseases, including uncontrolled hypertension and active bleeding diatheses, which in the investigator's opinion makes it undesirable for the subject to participate in the study or which would jeopardize compliance with the protocol, or active infection including human immunodeficiency virus (HIV) and untreated hepatitis B, hepatitis C. Screening for chronic conditions was not required.

8. Subjects who have received any investigational agent within the last 28 days were excluded from participation in this study.

9. Any acute toxicity due to prior chemotherapy and/or radiotherapy that has not resolved according to the Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Studies.

10. Known allergy, hypersensitivity, or intolerance to the IP or its excipients.

11. Subject unlikely to comply with study procedures, restrictions and requirements and judged by the investigator to be unsuitable for study participation.

• Minimum Eligible Age: 18 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: No

Sponsors

Advanced Accelerator Applications

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Novartis Pharmaceuticals

Role: STUDY_DIRECTOR

Novartis Pharmaceuticals

Locations

Pheonix Molecular Imaging Center

Phoenix, Arizona, United States

University of California, San Francisco (UCSF)

San Francisco, California, United States

Smilow Cancer Center at Yale New Haven

New Haven, Connecticut, United States

Johns Hopkins Hospital

Baltimore, Maryland, United States

National Institutes of Health, Warren Grant Magnusen Clinical Center

Bethesda, Maryland, United States

Countries

United States

Provided Documents

Document Type: Statistical Analysis Plan

View Document

Document Type: Study Protocol

View Document

Other Identifiers

CAAA502A12101

Identifier Type: OTHER

Identifier Source: secondary_id

A206D-A01-001

Identifier Type: -

Identifier Source: org_study_id